AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15515877
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin regimen (1 IU/h)
Trial: 11527675
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (30 g/d)
Trial: 9764549
Drug: Erythromycin estolate
RxNorm normalized name: Erythromycin Estolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin estolate at 40 mg/kg/day in two divided doses
Trial: 9764549
Drug: Amoxicillin at
RxNorm normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin at 50 mg/kg/day in two divided doses
Trial: 31801404
Drug: Broadband light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broadband light (BBL) treatment
Trial: 23786776
Drug: Tamoxifen 10
RxNorm normalized name: tamoxifen 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 10 mg/week
Trial: 11587974
Drug: Conservative Treatment
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative Treatment (CT) - sleep hygiene and weight loss
Trial: 2791799
Drug: Mealtime regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mealtime regimen (400 mg three times a day with meals)
Trial: 2791799
Drug: Bedtime regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedtime regimen (1200 mg at bedtime)
Trial: 2791799
Drug: Reference regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference regimen (200 mg three times a day with meals and 600 mg at bedtime)
Trial: 338025
Drug: Co-trimoxazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (10 ml by intravenous infusion)
Trial: 31635844
Drug: Indirect Pulp
RxNorm normalized name: acai fruit pulp
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect Pulp Therapy (IPT)
Trial: 27250495
Drug: Marginally low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marginally low Se-B (40-59 μg/l)
Trial: 27250495
Drug: Optimal Se-B
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal Se-B (≥80 μg/l)
Trial: 27250495
Drug: Suboptimal Se-B
RxNorm normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal Se-B (60-79 μg/l)
Trial: 19321587
Drug: 80 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg/d of isoflavones
Trial: 19321587
Drug: 120 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg/d of isoflavones
Trial: 9750706
Drug: Methylprednisolone (M)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (M) 30 mg.kg‐1 over 1 hour, followed by 5.4 mg.kg‐1.h‐1 for 23 hours
Trial: 9750706
Drug: Nimodipine (N)
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nimodipine (N) 0.015 mg.kg‐1.h‐1 over 2 hours followed by 0.03 mg.kg‐1.h‐1 for 7 days
Trial: 9750706
Drug: No medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medical treatment (P)
Trial: 31099632
Drug: Experimental arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experimental arm (new anticancer drugs)
Trial: 23820061
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm (standard treatment)
Trial: 27914033
Drug: L-carnitine 2
RxNorm normalized name: L-Carnitine 250mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 2 g/day plus simvastatin 20 mg/day
Trial: 27914033
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus simvastatin 20 mg/day
Trial: 21354368
Drug: Pramipexole (0.125-0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pramipexole (0.125-0.75 mg/d)
Trial: 18500518
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg p.o. with 20 mL antacid (1.6 g Al(OH)(3) + 1.6 g Mg(OH)(2)) 15 min before imatinib
Trial: 17413095
Drug: Normal calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal calcium intake (1 g/d) during weight loss
Trial: 17413095
Drug: High calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High calcium intake (1.8 g/d) during weight loss
Trial: 17413095
Drug: Weight maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight maintenance group (1 g Ca/d)
Trial: 12577419
Drug: Astragalus injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus injection (ASI) 20 ml in 500 ml 5% glucose solution, once a day for 2 months
Trial: 9701408
Drug: SR 48968
RxNorm normalized name: SR 121463
DrugBank: SR 121463 (DB05455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR 48968 (100 mg)
Trial: 31897483
Drug: Multinutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multinutrient supplementation (14 g l-arginine, 14 g l-glutamine, 1250 mg vitamin C, 55 mg zinc daily for 14 days before and after surgery)
Trial: 24595577
Drug: Existing DNA
RxNorm normalized name: Toxoplasma gondii DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existing DNA repair and antioxidant and growth factor topical products with SPF 50 sunscreens
Trial: 10190764
Drug: Oramorph SR
RxNorm normalized name: Oramorph SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oramorph SR 30 mg
Trial: 7436160
Drug: Aerosol metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol metaproterenol (5 puffs, 0.65 mg each, total 3.25 mg)
Trial: 7436160
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen (oral metaproterenol 20 mg + aerosol metaproterenol)
Trial: 7436160
Drug: Oral metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metaproterenol (20 mg tablet)
Trial: 23749293
Drug: BG-12 (dimethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BG-12 (dimethyl fumarate) three times daily (TID)
Trial: 9767368
Drug: Digoxin 0.25
RxNorm normalized name: digoxin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin 0.25 mg twice daily for 10 days
Trial: 9767368
Drug: Digitoxin 0.1
RxNorm normalized name: digitoxin 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digitoxin 0.1 mg daily for 10 days
Trial: 8121439
Drug: Hormonal factors
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal factors (oral contraceptives and high parity)
Trial: 3113804
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil (125 mg, twice daily)
Trial: 3113804
Drug: Phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl penicillin (250 mg, three times daily)
Trial: 26603245
Drug: Hydration group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydration group (n=17) coached to increase water intake by up to 1.5 L/day for 6 weeks
Trial: 1784882
Drug: Intravenous regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous regional administration of methylprednisolone (40 mg)
Trial: 26845030
Drug: Interpersonal psychotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interpersonal psychotherapy (IPT) plus treatment as usual (TAU)
Trial: 21696894
Drug: Disulfiram (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (0, 250, and 500 mg/d, p.o.)
Trial: 21696894
Drug: Ethanol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.4 g/kg i.v.)
Trial: 21696894
Drug: Disulfiram (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (500 mg/d, p.o.)
Trial: 10778866
Drug: Tyrosine intake
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tyrosine intake at varying levels (3.0, 4.5, 6.0, 7.5, 9.0, 10.5, and 12.0 mg x kg(‐1) x d(‐1))
Trial: 7870903
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (logarithmically increasing doses at 15-min intervals)
Trial: 30871768
Drug: Ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ulipristal acetate (UPA) treatment
Trial: 20832282
Drug: PCEA+AMB (PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA+AMB (PCEA with AMB of 5 mL every hour)
Trial: 20832282
Drug: PCEA+BI (PCEA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCEA+BI (PCEA with basal continuous infusion of 5mL/h)
Trial: 10828010
Drug: L-asparaginase during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Trial: 10828010
Drug: No L-asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No L-asparaginase during consolidation therapy in the medium-risk group (MRG)
Trial: 10828010
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen in ALL-BFM 90
Trial: 10828010
Drug: Standard-risk group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-risk group (SRG) treatment regimen
Trial: 10828010
Drug: Medium-risk group
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-risk group (MRG) treatment regimen
Trial: 10828010
Drug: High-risk group
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-risk group (HRG) treatment regimen
Trial: 8651156
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of meperidine
Trial: 8651156
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of midazolam
Trial: 2000050
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (clonidine plus hydralazine)
Trial: 6406198
Drug: Intraperitoneal (i.p.)
RxNorm normalized name: Intraperitoneal Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal (i.p.) insulin infusion
Trial: 6406198
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) insulin infusion
Trial: 6406198
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) insulin infusion
Trial: 27044507
Drug: Standard ECLS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard ECLS therapy at normothermia
Trial: 15303996
Drug: Weekly iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly iron supplements (108 mg iron) given for 10 weeks
Trial: 15303996
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no iron supplements)
Trial: 2104790
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg)
Trial: 272044
Drug: Fluoride solution
RxNorm normalized name: Apatate with Fluoride Solution
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoride solution application post-restoration
Trial: 28661170
Drug: Tablet computer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet computer
Trial: 23301240
Drug: Fluoridated toothpaste
RxNorm normalized name: sodium fluoride Toothpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoridated toothpaste (Colgate Dental Cream)
Trial: 19836169
Drug: Donepezil (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5mg daily for 3 days)
Trial: 16417782
Drug: Osteoking (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteoking (25 ml every other day for 10 days)
Trial: 16417782
Drug: Sanchi‐dansheng tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanchi‐dansheng tablets (3 tablets thrice a day for 10 days)
Trial: 16417782
Drug: Sanchi‐dansheng tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanchi‐dansheng tablets
Trial: 11575540
Drug: Ephedrine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (2 mg/min) plus phenylephrine (10 microg/min)
Trial: 11575540
Drug: Ephedrine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (2 mg/min) alone
Trial: 9663418
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 100 mg alizapride plus placebo (group A)
Trial: 9663418
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 100 mg alizapride plus 3 x 4 mg dexamethasone (group B)
Trial: 8176255
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% betamethasone dipropionate applied at 1600 h for 2 or 6 hours
Trial: 8176255
Drug: Topical 0.05%
RxNorm normalized name: ingenol topical 0.05% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.05% betamethasone dipropionate
Trial: 7486094
Drug: Morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.1 mg/kg IV
Trial: 2285605
Drug: Anandron (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anandron (300 mg) + orchiectomy
Trial: 20665554
Drug: Direct screening
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct screening (invitation by letter followed by a home visit to administer the GDS-15)
Trial: 19644132
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral nutritional supplement containing 1.3 mg of riboflavin for 6 weeks
Trial: 17442999
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with vinorelbine and cisplatin
Trial: 17442999
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (vinorelbine and cisplatin)
Trial: 26177937
Drug: Olodaterol 2.5
RxNorm normalized name: OLODATEROL 2.5MCG/ACTUAT 14D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol 2.5 μg BID
Trial: 25187881
Drug: Olodaterol 5
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 μg QD
Trial: 26177937
Drug: Olodaterol 5
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 μg BID
Trial: 25187881
Drug: Olodaterol 10
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 10 μg QD
Trial: 26177937
Drug: Olodaterol 5
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 5 μg QD vs Olodaterol 2.5 μg BID
Trial: 26177937
Drug: Olodaterol 10
RxNorm normalized name: Olodaterol
DrugBank: Olodaterol (DB09080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olodaterol 10 μg QD vs Olodaterol 5 μg BID
Trial: 26382173
Drug: Aggressive medical
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive medical therapy alone
Trial: 23500245
Drug: Aggressive medical
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive medical therapy with prompt revascularization
Trial: 21690555
Drug: High-dose cytarabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytarabine (HDAraC)
Trial: 21690555
Drug: Timed-sequential chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timed-sequential chemotherapy (TSC)
Trial: 8192452
Drug: Norfloxacin with
RxNorm normalized name: Norfloxacin
DrugBank: Norfloxacin (DB01059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norfloxacin with sucralfate (1 g)
Trial: 8192452
Drug: Ofloxacin with
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ofloxacin with sucralfate (1 g)
Trial: 18566197
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (patient-controlled analgesia morphine)
Trial: 15788122
Drug: Protein group
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein group (30 g/d protein)
Trial: 11954675
Drug: Experimental medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental medication
Trial: 2215987
Drug: Propofol injection
RxNorm normalized name: propofol Injection
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol injection for induction of anesthesia
Trial: 2215987
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of Diprivan (Propofol) for maintenance of anesthesia
Trial: 31087325
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of micronized vaginal progesterone once daily from 16-26 weeks until 36 weeks of gestation
Trial: 31087325
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily from 16-26 weeks until 36 weeks of gestation
Trial: 31087325
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg of micronized vaginal progesterone once daily
Trial: 27715351
Drug: Yeast β-glucan
RxNorm normalized name: yeast, beta-D-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yeast β-glucan 477 mg/capsule
Trial: 27056418
Drug: 7-day MAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day MAP treatment
Trial: 27056418
Drug: 14-day MAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day MAP treatment
Trial: 24372492
Drug: Immediate long
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate long license suspension
Trial: 3898010
Drug: Theophylline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (10 mg/kg for 2-6 months, 12 mg/kg for 6-12 months, 16 mg/kg for 12-24 months)
Trial: 29793828
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal testosterone gel (1.62%, 1.25 g)
Trial: 29793828
Drug: Full replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full replacement dose testosterone gel (1.62%, 5 g)
Trial: 29793828
Drug: Full replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full replacement dose testosterone gel with aromatase inhibitor
Trial: 24573122
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vitamins and n‐3 PUFAs
Trial: 25211364
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg·kg⁻¹)
Trial: 17333971
Drug: 81 mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 81 mg of acetylsalicylic acid (aspirin) ingested 24 hours before blood donation
Trial: 11575417
Drug: remifentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 0.5 microg kg(‐1) followed by an infusion of 0.1 microg kg min(‐1)
Trial: 11575417
Drug: alfentanil 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alfentanil 10 microg kg(‐1) followed by an infusion of saline
Trial: 7181051
Drug: High single
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High single dose (greater than or equal to 1,000 biological units)
Trial: 7181051
Drug: High nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nasal sensitivity before treatment
Trial: 7181051
Drug: Repetition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetition of a single dose
Trial: 7181051
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses (greater than or equal to 5,000 biological units)
Trial: 7181051
Drug: Initial preseasonal
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial preseasonal therapy
Trial: 7181051
Drug: Subsequent perennial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subsequent perennial dosage
Trial: 10396521
Drug: Interview administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interview administration of questionnaire
Trial: 10396521
Drug: Postal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postal administration of questionnaire